WuXi XDC and LigaChem Biosciences Strengthen Partnership with Expanded MOU to Accelerate ADC Development
SHANGHAI, Feb. 25, 2025 /PRNewswire/ -- WuXi XDC Cayman Inc. ("WuXi XDC", or the "Company", stock code: 2268.HK), a leading global CRDMO (Contract Research, Development, and Manufacturing Organization) specializing in antibody-drug conjugates (ADCs)...
Akeso Highlights Collaboration Between Its Partner Summit Therapeutics and Pfizer to Explore Ivonescimab in Combination with Pfizer's ADCs
HONG KONG, Feb. 25, 2025 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") today announced that its partner on ivonescimab, Summit Therapeutics Inc. (NASDAQ: SMMT) has entered into a clinical trial collaboration with Pfizer Inc....
Medicilon Appoints Dr. Lilly Xu as Chief Technology Officer
BOSTON, Dec. 20, 2024 /PRNewswire/ -- Medicilon, a leading preclinical contract research organization (CRO), has named Dr. Lilly Xu as its new Chief Technology Officer (CTO). With over 30 years of experience in preclinical drug development, Dr. Xu...
Porton Pharma Solutions and Aojin Life Sciences Announce Strategic Collaboration to Advance XDC Conjugate Drugs for Dual IND Filings in China and the U.S.
CHONGQING, China, Dec. 12, 2024 /PRNewswire/ -- Recently, Porton Pharma Solutions Ltd. ("Porton") announced a strategic partnership with Aojin Life Sciences (Yixing) Co., Ltd. ("Aojin Life Sciences"). Porton will provide comprehensive CDMO services...
WuXi XDC and Celltrion Sign MOU for Integrated Services for Antibody-Drug Conjugates (ADCs)
SHANGHAI and INCHEON, South Korea, Jan. 24, 2024 /PRNewswire/ -- WuXi XDC(2268.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO) focused on ADC and the other types of bioconjugate market, and Celltrion, Inc....